JP2007510629A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510629A5
JP2007510629A5 JP2006536645A JP2006536645A JP2007510629A5 JP 2007510629 A5 JP2007510629 A5 JP 2007510629A5 JP 2006536645 A JP2006536645 A JP 2006536645A JP 2006536645 A JP2006536645 A JP 2006536645A JP 2007510629 A5 JP2007510629 A5 JP 2007510629A5
Authority
JP
Japan
Prior art keywords
alkyl
oxadiazol
aryl
ethylsulfanylmethyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/032314 external-priority patent/WO2005040157A2/en
Publication of JP2007510629A publication Critical patent/JP2007510629A/ja
Publication of JP2007510629A5 publication Critical patent/JP2007510629A5/ja
Pending legal-status Critical Current

Links

JP2006536645A 2003-10-22 2004-10-21 新規ｍｃｈ受容体アンタゴニスト Pending JP2007510629A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51344903P 2003-10-22 2003-10-22
PCT/US2004/032314 WO2005040157A2 (en) 2003-10-22 2004-10-21 Novel mch receptor antagonists

Publications (2)

Publication Number Publication Date
JP2007510629A JP2007510629A (ja) 2007-04-26
JP2007510629A5 true JP2007510629A5 (https=) 2007-11-22

Family

ID=34520102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536645A Pending JP2007510629A (ja) 2003-10-22 2004-10-21 新規ｍｃｈ受容体アンタゴニスト

Country Status (5)

Country Link
US (1) US20070135485A1 (https=)
EP (1) EP1723126A2 (https=)
JP (1) JP2007510629A (https=)
CA (1) CA2542220A1 (https=)
WO (1) WO2005040157A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418965C (zh) 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
CN101309905A (zh) * 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
TW200800220A (en) * 2005-10-26 2008-01-01 Boehringer Ingelheim Int New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
US8329704B2 (en) 2005-12-21 2012-12-11 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use in MCH-1 mediated diseases
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8586792B2 (en) 2011-12-28 2013-11-19 Divi's Laboratories Ltd. Process for the preparation of 4-iodo-3-nitrobenzamide
US9422238B2 (en) 2012-06-01 2016-08-23 National University Of Singapore ICMT inhibitors
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
WO2022265993A1 (en) 2021-06-14 2022-12-22 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
WO2002074758A2 (en) * 2001-03-16 2002-09-26 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
WO2003087046A1 (en) * 2002-04-09 2003-10-23 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

Similar Documents

Publication Publication Date Title
JP2007510629A5 (https=)
US8436038B2 (en) Indole and indazole compounds as an inhibitor of cellular necrosis
ES2632597T3 (es) Compuestos intermedios para la preparación de derivados de 1-(acetil)-piperidina y 1-(acetil)-piperazina como fungicidas para usar en la protección de plantas
AU2009330686B2 (en) Compounds for the treatment of cancer
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2014511869A5 (https=)
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
RU2459812C2 (ru) Новое производное катехина, фармацевтическая композиция, содержащая производное катехина, применение производного катехина и применение фармацевтической композиции
JP2008513500A5 (https=)
JP2005529923A5 (https=)
CA2630269A1 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
JP2005534627A5 (https=)
US20150051185A1 (en) Chemical Compounds 251
JP2020533347A5 (https=)
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
JP2019537594A5 (https=)
JP2010513319A5 (https=)
JP2009525984A5 (https=)
JP2006505522A5 (https=)
JP2007531739A5 (https=)
RU2004104951A (ru) Замещенные пиперазиновые соединения и их применение в качестве ингибиторов окисления жирных кислот
CA2601709A1 (en) Beta-lactamylalkanoic acids
JP2005526732A5 (https=)
JP2018515489A5 (https=)